/
IONS
$78.49-$0.80 (-1.01%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$13.1B
165M shares
52-week range
$39.72 – $86.74
82% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$38.57
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $599.7M | $1.12B | $729.3M | $810.5M | $587.4M | $787.6M | $705.1M | $944.0M |
| Cost of revenue | $1.8M | $4.4M | $11.9M | $10.8M | $14.1M | $9.1M | $11.2M | $16.0M |
| Gross profit | $597.9M | $1.12B | $717.3M | $799.6M | $573.3M | $778.5M | $693.9M | $928.0M |
| Gross margin | 99.7% | 99.6% | 98.4% | 98.7% | 97.6% | 98.8% | 98.4% | 98.3% |
| R&D | $414.6M | $466.0M | $535.0M | $643.0M | $833.0M | $899.6M | $901.5M | $916.0M |
| Operating income | −$61.4M | $365.9M | −$172.1M | −$30.2M | −$410.2M | −$353.7M | −$475.1M | −$382.0M |
| EBITDA | −$18.8M | $367.2M | −$111.2M | −$5.2M | −$227.8M | −$235.9M | −$353.7M | −$286.7M |
| Net income | $273.7M | $278.1M | −$444.3M | −$28.6M | −$269.7M | −$366.3M | −$453.9M | −$381.0M |
| Net margin | 45.6% | 24.8% | -60.9% | -3.5% | -45.9% | -46.5% | -64.4% | -40.4% |
| EPS (diluted) | 2.04 | 2.06 | -3.18 | -0.20 | -1.90 | -2.56 | -3.04 | -2.38 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $893M | $-3.61 | $-3.69–$-3.46 | 10 |
| 2027 | $1.5B | $-1.14 | $-2.07–$-0.61 | 10 |
| 2028 | $2.2B | $1.43 | $-4.36–$5.80 | 14 |
| 2029 | $2.9B | $4.62 | $3.83–$5.72 | 8 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
www.ionis.com- Employees
- 1,402
- IPO / List date
- May 17, 1991
- HQ
- CARLSBAD, CA
Held by traders on TradeandTell
No one on the platform currently holds IONS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 305,549 | $22.9M |
| Bridgewater Associatesas of 2025-12-31 | 67,706 | $5.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IONS yet.
